Brief Summary
This study aims to evaluate the feasibility and benefits of molecular screening in participants with haematological malignancies.
Intervention/Treatment
- Nil.
Inclusion Criteria
- Participants, aged 18 years and older, with pathologically confirmed blood cancer at initial diagnosis or relapse/refractory disease.
- Sufficient and accessible tissue for molecular screening.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
- Willing and potentially able to comply with study requirements.
- Signed, written informed consent to participation in the molecular screening.